Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.

ABSTRACT:

Background

Antibodies against the programmed death-1 (PD-1) receptor and its ligand (PD-L1) have been recently approved for small-cell lung cancer (SCLC) treatment. Circulating tumour cells (CTCs) have emerged as an appealing liquid biopsy candidate that could enhance treatment decision-making in systemic therapy for SCLC patients. Several current technologies enrich CTCs using specific surface epitopes, size, rigidity, or dielectric properties. However, they are hampered by the heterogeneity of the enriched cells from blood samples.

Methods

We evaluated two CTC enrichment systems: EpCAM conjugated to magnetic beads and a microfluidic device (Parsortix, Angle plc). PD-L1 expression was evaluated on the isolated CTCs. Twenty-three blood samples were collected from 21 patients

SUBMITTER: Acheampong E 

PROVIDER: S-EPMC8988079 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature